Therapeutic Agents for the Treatment of Lymphoid Malignancies

Abstract

Methods—for treatment and prevention of lymphoid malignancies, including, but not limited to acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), B-cell lymphoma, Acute Myeloid leukemia (AML), and mantle cell lymphoma (MCL). The methods include administration of a therapeutically effective amount of FTY720 (2-Amino-2-[2-(4-octylphenyl)ethyl]propane 1,3-diol hydrochloride) or a derivative, pharmaceutically acceptable salt thereof, or a prodrug thereof to a subject.

1 . A method of treating acute myeloid leukemia (AML) in a subject, the method comprising the step of
 administering a therapeutically effective amount of 2-Amino-2-[-(4-octylphenyl)ethyl]propane 1,3-diol hydrochloride or a pharmaceutically acceptable salt thereof   to a subject in need of such treatment.   
     
     
         2 . (canceled) 
     
     
         3 . The method of  claim 1  wherein the subject is refractory to other treatments. 
     
     
         4 . The method of  claim 1  wherein the subject is a human subject. 
     
     
         5 . A method of preventing acute myeloid leukemia (AML) in a subject, the method comprising the step of
 administering a therapeutically effective amount of 2-Amino-2-[2-(4-octylphenyl)ethyl]propane 1,3-diol hydrochloride or a pharmaceutically acceptable salt thereof,   to a subject at risk of developing acute myeloid leukemia (AML).   
     
     
         6 . (canceled) 
     
     
         7 . The method of  claim 5  wherein the subject is a human subject. 
     
     
         8 . A method of inducing apoptosis in acute myeloid leukemia (AML) in a subject, the method comprising the step of
 administering a therapeutically effective amount of 2-Amino-2-[2-(4-octylphenyl)ethyl]propane 1,3-diol hydrochloride or a pharmaceutically acceptable salt thereof,   to a subject in need of such treatment.   
     
     
         9 . (canceled) 
     
     
         10 . The method of  claim 8  wherein the subject is a human subject. 
     
     
         11 . The method of  claim 1 , further comprising the step of administering a therapeutically effective amount of an additional antineoplastic agent. 
     
     
         12 . The method of  claim 8 , wherein the subject is a human subject.